Should I buy or sell C4 Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for C4 Therapeutics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CCCC shares. View CCCC analyst ratings or view top-rated stocks .

What is C4 Therapeutics' stock price target for 2024?

6 Wall Street analysts have issued twelve-month price objectives for C4 Therapeutics' shares. Their CCCC share price targets range from $2.00 to $20.00. On average, they expect the company's share price to reach $10.25 in the next twelve months. This suggests a possible upside of 52.5% from the stock's current price. View analysts price targets for CCCC or view top-rated stocks among Wall Street analysts .

How have CCCC shares performed in 2024?

C4 Therapeutics' stock was trading at $5.65 at the beginning of 2024. Since then, CCCC stock has increased by 18.9% and is now trading at $6.72. View the best growth stocks for 2024 here .

Are investors shorting C4 Therapeutics?

C4 Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 9,150,000 shares, an increase of 73.0% from the March 15th total of 5,290,000 shares. Based on an average daily volume of 3,740,000 shares, the short-interest ratio is presently 2.4 days. View C4 Therapeutics' Short Interest .

When is C4 Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CCCC earnings forecast .

How were C4 Therapeutics' earnings last quarter?

C4 Therapeutics, Inc. (NASDAQ:CCCC) issued its earnings results on Thursday, February, 22nd. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by $0.01. The business earned $3.26 million during the quarter, compared to analyst estimates of $5.23 million. C4 Therapeutics had a negative net margin of 638.34% and a negative trailing twelve-month return on equity of 55.30%.

What ETF holds C4 Therapeutics' stock?

Harbor Disruptive Innovation ETF holds 31,984 shares of CCCC stock, representing 0.70% of its portfolio.

When did C4 Therapeutics IPO?

C4 Therapeutics (CCCC) raised $150 million in an initial public offering on Friday, October 2nd 2020. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank acted as the underwriters for the IPO.

Who are C4 Therapeutics' major shareholders?

C4 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (6.31%). Insiders that own company stock include Adam Crystal , Andrew Hirsch, Elena Prokupets , Jolie Siegel , Malcolm Salter , Stewart Fisher and Utpal Koppikar. View institutional ownership trends .

How do I buy shares of C4 Therapeutics?

Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CCCC

C4 Therapeutics (CCCC) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free CCCC Stock Alerts

$6.72

-0.19 (-2.75%)

(As of 04/19/2024 ET)

Compare

Today's Range: $6.53
▼
$7.16
50-Day Range: $6.53
▼
$11.00
52-Week Range: $1.06
▼
$11.88

Volume: 1.73 million shs
Average Volume: 1.32 million shs
Market Capitalization: $460.99 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.25

Get C4 Therapeutics alerts:

C4 Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 52.5% Upside
$10.25 Price Target
Short Interest: Bearish
13.34% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.34
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.86) to ($2.07) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.09 out of 5 stars

Medical Sector

764th out of 912 stocks

Biological Products, Except Diagnostic Industry

130th out of 150 stocks

3.3

Analyst's Opinion

Consensus Rating
C4 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
C4 Therapeutics has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
13.34% of the outstanding shares of C4 Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
C4 Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in C4 Therapeutics has recently increased by 72.97%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
C4 Therapeutics does not currently pay a dividend.
Dividend Growth
C4 Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CCCC.

1.9

News and Social Media Coverage

News Sentiment
C4 Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for C4 Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 22 people have searched for CCCC on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added C4 Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, C4 Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.97% of the stock of C4 Therapeutics is held by insiders.
Percentage Held by Institutions
78.81% of the stock of C4 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for C4 Therapeutics are expected to decrease in the coming year, from ($1.86) to ($2.07) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of C4 Therapeutics is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of C4 Therapeutics is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
C4 Therapeutics has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad American Alternative

Your Money is Not Safe

Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…

CLICK HERE TO GET YOUR GUIDE NOW

About C4 Therapeutics Stock (NASDAQ:CCCC)

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

CCCC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CCCC Stock News Headlines

April 14, 2024 | americanbankingnews.com

C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Rating of "Moderate Buy" by Analysts

April 14, 2024 | americanbankingnews.com

C4 Therapeutics (NASDAQ:CCCC) Trading Up 3.2%

April 20, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 12, 2024 | americanbankingnews.com

C4 Therapeutics (NASDAQ:CCCC) Shares Gap Down to $7.97

April 11, 2024 | seekingalpha.com

Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation

April 9, 2024 | globenewswire.com

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

April 8, 2024 | msn.com

C4 Dips on Release of Data

April 8, 2024 | finance.yahoo.com

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

April 20, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 8, 2024 | globenewswire.com

March 28, 2024 | finance.yahoo.com

Here’s Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC)

March 16, 2024 | finance.yahoo.com

CCCC Mar 2024 17.000 call

March 16, 2024 | finance.yahoo.com

CCCC Mar 2024 10.000 put

March 9, 2024 | nasdaq.com

Guru Fundamental Report for CCCC

March 5, 2024 | globenewswire.com

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

March 4, 2024 | globenewswire.com

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

March 2, 2024 | finance.yahoo.com

CCCC Mar 2024 9.000 call

March 1, 2024 | seekingalpha.com

C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched

February 27, 2024 | finance.yahoo.com

New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

February 26, 2024 | markets.businessinsider.com

Breaking Down C4 Therapeutics: 4 Analysts Share Their Views

February 25, 2024 | finance.yahoo.com

CCCC Mar 2024 8.500 put

February 24, 2024 | ca.finance.yahoo.com

CCCC Mar 2024 7.000 put

February 24, 2024 | finance.yahoo.com

C4 Therapeutics Full Year 2023 Earnings: Misses Expectations

February 23, 2024 | markets.businessinsider.com

Strong Financials and Promising Drug Pipeline Bolster Buy Rating for C4 Therapeutics

February 23, 2024 | realmoney.thestreet.com

C4 Therapeutics price target raised by $1 at Stifel, here's why

February 22, 2024 | benzinga.com

C4 Therapeutics Stock (NASDAQ:CCCC) Insider Trades

February 22, 2024 | finanznachrichten.de

C4 Therapeutics, Inc.: C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

See More Headlines

Receive CCCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:CCCC
CUSIP: N/A
CIK: 1662579
Web: www.c4therapeutics.com
Phone: 617-231-0700
Fax: N/A
Employees: 145
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.25
High Stock Price Target: $20.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +52.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.67)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-132,490,000.00
Net Margins: -638.34%
Pretax Margin: -632.17%
Return on Equity: -55.30%
Return on Assets: -35.80%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.34
Quick Ratio: 6.34

Sales & Book Value

Annual Sales: $20.76 million
Price / Sales: 22.21
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.07 per share
Price / Book: 1.65

Miscellaneous

Outstanding Shares: 68,600,000
Free Float: 63,134,000
Market Cap: $460.99 million
Optionable: Optionable
Beta: 3.18

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Andrew J. Hirsch M.B.A. (Age 53)
CEO, President & Director
Comp: $971k
Dr. Kenneth C. Anderson M.D. (Age 73)
Ph.D., Co-Founder, Independent Director & Member of Scientific Advisory Board
Comp: $39.03k
Dr. Stewart Fisher (Age 57)
Chief Scientific Officer
Comp: $657.34k
Mr. Scott N. Boyle M.B.A. (Age 46)
Ph.D., Chief Business Officer
Comp: $672.78k
Dr. Nathanael S. Gray Ph.D.
Co-Founder & Member of Scientific Advisory Board
Ms. Kendra Adams
Chief Financial Officer
Mr. Mark Mossler (Age 51)
Chief Accounting Officer
Ms. Jolie M. Siegel J.D. (Age 47)
Chief Legal Officer & Corporate Secretary
Comp: $610.4k
Ms. Kelly A. Schick (Age 44)
Chief People Officer
Dr. Isabel Chiu Ph.D.
Senior Vice President of Strategic Alliances & Business Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CCCC Stock Analysis - Frequently Asked Questions

Should I buy or sell C4 Therapeutics stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for C4 Therapeutics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CCCC shares.
View CCCC analyst ratings or view top-rated stocks.
What is C4 Therapeutics' stock price target for 2024?: 6 Wall Street analysts have issued twelve-month price objectives for C4 Therapeutics' shares. Their CCCC share price targets range from $2.00 to $20.00. On average, they expect the company's share price to reach $10.25 in the next twelve months. This suggests a possible upside of 52.5% from the stock's current price.
View analysts price targets for CCCC or view top-rated stocks among Wall Street analysts.
How have CCCC shares performed in 2024?: C4 Therapeutics' stock was trading at $5.65 at the beginning of 2024. Since then, CCCC stock has increased by 18.9% and is now trading at $6.72.
View the best growth stocks for 2024 here.
Are investors shorting C4 Therapeutics?: C4 Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 9,150,000 shares, an increase of 73.0% from the March 15th total of 5,290,000 shares. Based on an average daily volume of 3,740,000 shares, the short-interest ratio is presently 2.4 days.
View C4 Therapeutics' Short Interest.
When is C4 Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CCCC earnings forecast.
How were C4 Therapeutics' earnings last quarter?: C4 Therapeutics, Inc. (NASDAQ:CCCC) issued its earnings results on Thursday, February, 22nd. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by $0.01. The business earned $3.26 million during the quarter, compared to analyst estimates of $5.23 million. C4 Therapeutics had a negative net margin of 638.34% and a negative trailing twelve-month return on equity of 55.30%.

What ETF holds C4 Therapeutics' stock?: Harbor Disruptive Innovation ETF holds 31,984 shares of CCCC stock, representing 0.70% of its portfolio.
When did C4 Therapeutics IPO?: C4 Therapeutics (CCCC) raised $150 million in an initial public offering on Friday, October 2nd 2020. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank acted as the underwriters for the IPO.
Who are C4 Therapeutics' major shareholders?: C4 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (6.31%). Insiders that own company stock include Adam Crystal, Andrew Hirsch, Elena Prokupets, Jolie Siegel, Malcolm Salter, Stewart Fisher and Utpal Koppikar.
View institutional ownership trends.
How do I buy shares of C4 Therapeutics?: Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CCCC) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial